tbuckley/cabot-search huggingface dataset:
Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities
Authors: Elias J. Jabbour, Hagop M. Kantarjian, Betul Oran, Farhad Ravandi, Hady Ghanem, Issa Khouri, Guillermo Garcia-Manero, Michael S Mathisen, Qaiser Bashir, Rima M Saliba, Maria Khouri, Sherry A. Pierce, Mark Brandt, Richard E. Champlin, Marcos De Lima
Journal: Blood (2012)
PWE-055 Coeliac Disease is More Common in Subjects with Postural Orthostatic Tachycardia Syndrome Compared to Healthy Controls
Authors: HA Penny, I Aziz, M Ferrar, J Atkinson, N Hoggard, M Hadjivassiliou, JN West, DS Sanders
Journal: Gut (2016)

<h3>Introduction</h3> Patients with the postural tachycardia syndrome (PoTS) have anecdotally reported symptom improvement on a gluten-free diet (GFD) but there has been no association study between PoTS and coeliac disease. Therefore, we aimed to evaluate the prevalence of coeliac disease and self-reported gluten sensitivity in a cohort of patients with PoTS and compare this with local population data. <h3>Methods</h3> 100 PoTS patients were recruited from the syncope clinic to complete a validated questionnaire which screened for gluten sensitivity and related symptoms. Case notes were reviewed for relevant GI diagnoses. For comparison, the local coeliac prevalence was determined from a total of 1200 controls (Control Group 1) and a further 400 controls (Control Group 2; frequency matched for age and sex) filled out the same questionnaire. <h3>Results</h3> Four out of a hundred (4%) patients with PoTS had serology and biopsy-proven coeliac disease. This was significantly higher than the prevalence of coeliac disease in Control Group 1 (12/1200, 1%; OR 4.1, 95% CI 1.3 to 13.0; p = 0.02). In comparison with Control Group 2, patients with PoTS had a higher prevalence of self-reported gluten sensitivity (42% versus 19%; p &lt; 0.001), coeliac disease (4% versus 1%; p = 0.04) and IBS (36% versus 9%; p &lt; 0.0001). <h3>Conclusion</h3> There is a high prevalence of coeliac disease and self-reported gluten sensitivity in patients with PoTS. We advocate screening for the gluten-related disorders in patients with PoTS. Further studies are required to ascertain the nature of this relationship. <h3>Disclosure of Interest</h3> None Declared
Identification of a Gain-of-Function SNP Causing a New Model of α-Thalassaemia.
Authors: Marco De Gobbi, Vip Viprakasit, Pieter J. de Jong, Yuko Yoshinaga, Jan-Fang Cheng, Jim R. Hughes, Chris A. Fisher, William G. Wood, Donald K. Bowden, Douglas R. Higgs
Journal: Blood (2005)
FRI0528 Epidemiological and Clinical Relationship of Ultrasonographic Features of Acute Anserine Syndrome
Authors: C.A. Guillen Astete, G. Silvestre-Egea, A. Boteanu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Anserine syndrome (AS) includes two pathological presentarions: The anserine bursitis and the anserine enthensytis. Most diagnostics of anserine syndrome are made considering topographic semiotics. It is logical to assume that treatment of different physiopathological features are associated with different clinical history but not necessary with differences in the clinical exam. <h3>Objectives</h3> To find relationships between ultrasonographic (US) findings and epidemiological data in patients with anserine syndrome <h3>Methods</h3> All the images of ultrasonographic studies of patients from 2013 to 2014 who were clinically assessed due to AS were reviewed. For that purpose we use the electronic database of the A&amp;E department. Gender, age, and time from onset of symptoms were used to find correlation with US findings. US assessments were performed by two trained rheumatologist using standard Eular definitions as part of common clinical practice during the period selected. Findings considered positive were: bursitis and enthesitis. <h3>Results</h3> 113 registries which fulfilled the clinical diagnostic criteria were analyzed with their corresponding ultrasonographic images. 38 cases were unrelated to any particular ultrasonogrpahic finding, 20 were compatible with bursitis and 56 with enthesitis. Average age in the three groups were 69 SD 8, 46 SD 7 and 55 SD 9 years old (<i>P</i>&lt;0.0001). Patients with bursitis where significantly younger than patients with enthesitis (<i>P</i>=0.0001). Also, patients without findings were significantly older than both other groups (<i>P</i>&lt;0.0001 for both comparisons). Proportion of female gender was 58.9%, 65,0% and 53.6%, in enthesitis, bursitis and no-findings group, respectively (<i>P</i>=0.647). According to time since onset of symptoms, patients with less than a week presented bursitis and enthesitis in 55.17% and 34.48%, respectively. Patients with symptoms within 7 to 14 days presented bursitis and enthesitis in a proportion of 6.67% and 46.67%, respectively. Finally patients with symptoms within 15 days and less than a month presented bursitis in 2.56% and enthesitis in 64.10%. Bursitis was significantly higher in patients with acute symptomps compared to the other two groups (<i>P</i>&lt;0.001). In the other hand, most patients with enthesitis were classified into the groups with a longer time since onset of symptoms (<i>P</i>&lt;0.05) <h3>Conclusions</h3> Our results point as Follows: (1) The probability of identify no US findings is higher in older patients than younger. It is possible that mechanical issues related with the collateral ligament could cause a pain that suggest an anserine syndrome. (2) As earlier the symptoms are, is more factible the finding of bursitis. It could suggest that bursitis is a sign of acuteness. This finding could have relevance in terms of infiltration indication. <h3>Disclosure of Interest</h3> None declared
AB0803 Chronic Kidney Disease Does Not Affect The Number of The Attacks and The Attack Durations in Gout Patients: Table 1.
Authors: Y. Özdem İnan, N. Alpay Kanıtez, S. Çelik, S. Yılmaz Öner, B. Yılmazer, C. Bes
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout is one of the most severe and frequent rheumatic diseases. Clinical manifestations of gout arise from uric acid crystal deposition in the musculoskeletal tissue. Many patients with gout have co-morbidities, including hypertension and chronic kidney disease (CKD). <h3>Objectives</h3> The goals when treating gout are no different in these patients, but the choice and dosage of drugs may need to be modified. In this study, we aimed to determine whether the chronic kidney disease affects or not the number of the gout attacks. <h3>Methods</h3> Consecutively 31 gout patients with CKD (group 1, n=31) and 46 gout patients without CKD (group 2, n=46) were enrolled in the study. The gout attack durations and the number of the gout attack in the last one year were compared among groups. <h3>Results</h3> The clinical, demographical and anthropometric variables were presented on table 1. There were no statistical differences in body mass index, use of diuretics and history of nephrolithiasis between two groups (p&gt;0.05 for all). Compared to group 2, group 1 had statistically similar levels of the gout attack durations and the number of the gout attacks in the last one year (both p&gt;0.05). In Bivariate Pearson correlation analysis; gout attack durations and the number of the gout attacks in the last one year were not correlated in any parameters in group 1 (p&gt;0.05 for all). <h3>Conclusions</h3> The present study revealed that CKD does not affect the number of the attacks and the attack durations in gout patients. Future large scale multicenter randomized controlled studies are needed and warranted to clarify our results. <h3>Disclosure of Interest</h3> None declared
Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS
Authors: Uday Popat, Rima Saliba, Leandro de Padua Silva, Borje S Andersson, Amin M Alousi, Paolo Anderlini, Marcos de Lima, Grace-Julia Okoroji, Chitra M Hosing, Roy B Jones, Partow Kebriaei, Issa Khouri, Yago Nieto, Muzaffar H Qazilbash, Richard Champlin, Sergio A Giralt
Journal: Blood (2008)
FRI0118 Carotid Ultrasonography and Ankle-Brachial Index in The Cardiovascular Risk Assessment of Patients with Rheumatoid Arthritis: Table 1.
Authors: A. Ricioppo, A. Menghini, H. Polo Friz, G. Marano, L. Primitz, M. Molteni, G. Arpaia, P. Boracchi, C. Cimminiello
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) associates with higher mortality rates than general population, mostly due to cardiovascular (CV) disease [1]. Guidelines recommend CV risk assessment in all RA patients. The European League against Rheumatism (EULAR) has proposed a modified version of SCORE risk estimation system (mSCORE) [2]. Few studies assessed the impact of an increased carotid intima media thickness (cIMT), carotid plaques, and ankle-brachial index (ABI) on the CV risk assessment in patients with RA. <h3>Objectives</h3> To assess whether the value of carotid ultrasonography and ABI in the stratification of CV risk in RA. <h3>Methods</h3> All RA patients who consecutively attended the outpatient rheumatology clinic of our hospital were enrolled. Exclusion criteria: diabetes mellitus, history of cardio and cerebrovascular events and age&gt;75 years old. <h3>Results</h3> The study population was represented by 78 patients, 61 women (78.2%), median age 60 years old and disease duration 6.0 years. The SCORE (median) and EULAR mSCORE were 1.25 and 1.5. All patients with an abnormal ABI had a normal cIMT. 27/78 (34.6%) patients had High CV risk defined as a)mSCORE ≥5% or b)mSCORE&lt;5% plus cIMT&gt;0.90 mm and/or plaques or an abnormal ABI. A SCORE&gt;5% had a Sensitivity of 29.6% (8/27), an Abnormal ABI 14.8% (4/27), a cIMT&gt;0.90mm plus carotid plaques 70.4% (19/27), a mSCORE&lt;5% plus Abnormal ABI 14.8% (4/27), a mSCORE&lt;5% plus cIMT&gt;0.90mm and/or carotid plaques 55.6% (15/27) and an Abnormal ABI plus cIMT&gt;0.90mm and/or carotid plaques 85.2% (23/27). <h3>Conclusions</h3> SCORE showed a low sensitivity to identify high risk RA patients, and mSCORE did not improve it. Carotid ultrasonography assessment showed a higher sensitivity than mSCORE and ABI to detect high CV risk. Despite its low sensitivity, an abnormal ABI identify high risk patients not discriminated by using mSCORE nor cIMT. Carotid ultrasound seems to be more sensitive than ABI, SCORE and mSCORE to identify high CV risk in patients with RA. <h3>References</h3> Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care 2012; 18: S295-S302. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325e31. <h3>Disclosure of Interest</h3> None declared
Bone Marrow Transplantation and Immunosuppressive Therapy in Children with Aplastic Anemia: Data from a Prospective Multinational Trial in Germany, Austria and Switzerland.
Authors: Monika M. Fuehrer, Udo Rampf, Charlotte M. Niemeyer, Andreas Faldum, Irith Baumann, Wilhelm Friedrich, Wolfram Ebell, Arndt Borkhardt, Christine Bender-Goetze
Journal: Blood (2004)
FRI0150 Depression, Inflammation and Mortality in Patients with Rheumatoid Arthritis
Authors: S. Kleinert, A. Marx, H. Faller, H.-P. Tony, M. Feuchtenberger, C. Kneitz, S. Lehmann, C. Angermann, G. Ertl, S. Störk, M. Breunig
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) have a high prevalence of depressive symptoms and an increased mortality. <h3>Objectives</h3> The current prospective follow-up study investigates prevalence of depression, its association with inflammation and mortality in RA patients. <h3>Methods</h3> 764 consecutive patients attending the rheumatology outpatient department of the University Hospital Würzburg underwent a comprehensive cardiovascular (CV) risk assessment. Inflammation in RA patients was characterized by DAS28 and CRP. Quality of life and depressive symptoms were investigated by SF-36 and PHQ-9 (range 0–27 score points), respectively. A PHQ score ≥15 points is considered indicative for severe depressive symptoms. <h3>Results</h3> 352 subjects suffered from rheumatoid arthritis (RA: 79.5% female, 64.9% RF positive, mean age 54.3 (SD 14.3)), Severe or moderate depressive symptoms were prevalent in 6.6%, respectively 14.4% of RA patients. DAS28, but not CRP, was significantly associated with the prevalence of depressive symptoms (r=0.26 (p&lt;0.001), figure A, table 1). Patients with severe depressive symptoms (PHQ 9 ≥15) had an increased a HR of 6.42 (95% CI, 2.04 – 20.2, p=0.004) for mortality compared to patients with a PHQ ≤14 (figure B). <h3>Conclusions</h3> DAS28 in RA patients was associated with severity of depressive symptoms. Severely depressed patients had an increased mortality. <h3>Disclosure of Interest</h3> None declared
Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters
Authors: Johannes Matthaei, Mladen V. Tzvetkov, Valerie Gal, Cordula Sachse-Seeboth, Daniel Sehrt, Jakob B. Hjelmborg, Ute Hofmann, Matthias Schwab, Reinhold Kerb, Jürgen Brockmöller
Journal: Genome Medicine (2016)

Efflux transporters like MDR1 and MRP2 may modulate the pharmacokinetics of about 50 % of all drugs. It is currently unknown how much of the variation in the activities of important drug membrane transporters like MDR1 or MRP2 is determined by genetic or by environmental factors. In this study we assessed the heritability of the pharmacokinetics of talinolol as a putative probe drug for MDR1 and possibly other membrane transporters. Talinolol pharmacokinetics were investigated in a repeated dose study in 42 monozygotic and 13 same-sex dizygotic twin pairs. The oral clearance of talinolol was predefined as the primary parameter. Heritability was analyzed by structural equation modeling and by within- and between-subject variance and talinolol clearance was correlated with polymorphisms in MDR1, MRP2, BCRP, MDR5, OATP1B1, and OCT1. Talinolol clearance varied approximately ninefold in the studied sample of healthy volunteers. The correlation of clearances between siblings was not significantly different for the monozygotic and dizygotic pairs. All data analyses consistently showed that variation of talinolol pharmacokinetics was mainly determined by environmental effects. Structural equation modeling attributed 53.5 % of the variation of oral clearance to common environmental effects influencing both siblings to the same extent and 46.5 % to unique environmental effects randomly affecting individual subjects. Talinolol pharmacokinetics were significantly dependent on sex, body mass index, total protein consumption, and vegetable consumption. The twin study revealed that environmental factors explained much more of the variation in pharmacokinetics of talinolol than genetic factors. European clinical trials database number: EUDRA-CT 2008-006223-31. Registered 26 September 2008. ClinicalTrials.gov number: NCT01845194 .
PTH-132 Medical Students’ Perception of Nutrition Education at An Undergraduate Level and The Role of The Clinicians They Shadow
Authors: P Neild, W Long
Journal: Gut (2016)

<h3>Introduction</h3> Medical schools have neglected nutrition training in undergraduate courses, resulting in medical students being unsure of its importance<sup>1 </sup>and doctors not confident in managing nutrition-related problems.<sup>2</sup> The aim of this study was to explore medical students’ views and experiences of nutrition training at different stages of their training and to evaluate the impact of the views of the clinicians they shadowed. <h3>Methods</h3> A cross-sectional email survey of all medical students in the first (T) and final (F) clinical years at St. George’s University of London was conducted. Clinicians at St. George’s hospital were surveyed with a 10 item questionnaire. Data were analysed using SPSS version 21.0 and the significance determined using a 2 tailed Fischer’s exact test. <h3>Results</h3> The overall student response rate was 106/549 (19.3%) with no significant difference between the 2 year groups. 86/~500 clinicians responded. 75% of students agreed that ‘having a strong understanding of nutrition is an important aspect of a doctor’s job’. Of those that disagreed, 57% cited as a reason that ‘other members of the healthcare team deal with nutrition problems’. 71% of students agreed that ‘nutrition should be included in the undergraduate medical curriculum’. The only students to disagree were from F year (12% vs 0%, p = 0.016) and 36% of them cited as a reason that their ‘medical school timetable is too full’. Only 11% of students had had the importance of nutrition highlighted to them by a senior clinician ‘regularly’. This group were more likely to ‘strongly agree’ with the statements above than those who had not (24% vs 3%, P = 0.02 and 21% vs 6%, P = 0.039). However, only 17% of clinicians frequently emphasised the importance of nutrition problems and only 7% frequently emphasised the importance of nutrition screening tools to students. The most commonly cited reason for clinicians not emphasising these was ‘it does not occur to me’ Only 50% of clinicians said they were confident managing nutrition related problems and for the majority (63.4%) of confident clinicians, it took greater than one year as a doctor to achieve this confidence. <h3>Conclusion</h3> It appears that whilst senior clinicians do have an impact on how students perceive the importance of nutrition, they do not emphasise it enough and; this may be due to themselves viewing it as a low priority or a lack of confidence. The greater likelihood of F year students disagreeing with nutrition’s inclusion in the curriculum may result from increased time spent on clinical placements compared with T year students, allowing their perception of nutrition to be negatively influenced by the clinicians they shadowed. <h3>References</h3> 1 Tripisciano F, Neild P. <i>Proceedings of the Nutrition Society</i>. 2010;<b>69</b>(0CE2). 2 Nightingale JM, <i>et al</i>. <i>Clin Nutr</i>. 1999;<b>18</b>(1):23–27. <h3>Disclosure of Interest</h3> None Declared
Isopentenyl Pyrophosphate (IPP), a Metabolite produced in Myeloma Cells Induces the Chemotaxis of γδT Cells
Authors: Eishi Ashihara, Tatsuya Munaka, Shinya Kimura, Masaki Kanai, Hirohisa Abe, Hideyo Hirai, Shuichi Shoji, Taira Maekawa
Journal: Blood (2010)
CXCR4 and CD62L Down-Regulation Following B-Cell Receptor Ligation Is Restricted to Progressive Chronic Lymphocytic Leukemia (CLL) Cases.
Authors: Amalia Vlad, Pierre-Antoine Deglesne, Remi Letestu, Nathalie Chevallier, Fanny Baran-Marszak, Nadine Varin-Blank, Florence Cymbalista, Dominique Ledoux
Journal: Blood (2007)
Most Primitive Murine Bone Marrow Hematopoietic Stem Cells Express Several Primordial Germline Cells (PGCs) Markers, Including SALL4 - a Proposed Developmental Link Between Hematopoietic and Primordial Germ Cell Lineages
Authors: Magdalena Kucia, Kasia Mierzejewska, Dong-Myung Shin, Yupo Ma, Mariusz Z Ratajczak
Journal: Blood (2012)
Implication of Genetic Variations of Ikzf1, ARIDB5, and CEBPE Genes In the Risk of Childhood Acute Lymphoblastic Leukemia In Korea
Authors: Dong Kyun Han, Hee Nam Kim, Min Ho Shin, Minenori Eguchi-Ishimae, Mariko Eguchi, Eiichi Ishii, Hee Jo Baek, Sun Ju Park, Hyeoung Joon Kim, Tai Ju Hwang, Hoon Kook
Journal: Blood (2010)
SP0156 How To Collect Comorbidities
Authors: E. Nikiphorou
Journal: Annals of the Rheumatic Diseases (2016)

The need to better understand and quantify the impact of comorbidity on patients and survival is well-recognised and forms an important area both for routine clinical practice and also for future research. However, there remain several challenges to overcome, a key one being the identification of optimal ways to accurately and consistently collect and measure comorbidity. To date, effective, simple and validated instruments to collect and aggregate comorbidity data are lacking. As a result, standard assessment and care for comorbidity varies considerably in rheumatology departments. Standardised ways for capturing data are therefore necessary for good quality research but more importantly for optimising patient care, quality of life, outcomes and prognosis. This talk reviews ways of collecting comorbidities in rheumatoid arthritis based on the existing literature, discussing general and disease-specific “indices” for quantifying comorbidity burden. <h3>Disclosure of Interest</h3> None declared
Factors influencing the spread of pertussis in households: a prospective study, Catalonia and Navarre, Spain, 2012 to 2013
Authors: Pere Godoy, Manuel García-Cenoz, Diana Toledo, Glòria Carmona, Joan A Caylà, Miquel Alsedà, Josep Àlvarez, Irene Barrabeig, Neus Camps, Pere Plans, María Company, Jesús Castilla, Maria-Rosa Sala-Farré, Carmen Muñoz-Almagro, Cristina Rius, Àngela Domínguez
Journal: Eurosurveillance (2016)

We aimed to investigate transmission rates of pertussis in household contacts of cases and factors associated with transmission. A prospective epidemiological study was conducted in 2012 and 2013 to determine the incidence of pertussis among household contacts of reported cases in Catalonia and Navarre, Spain. An epidemiological survey was completed for each case and contact, who were followed for 28 days to determine the source of infection (primary case) and detect the occurrence of secondary cases. Odds ratios (ORs) were used to estimate the effectiveness of vaccination and chemoprophylaxis in preventing new cases, using the formula (1 - OR) × 100. For the 688 primary cases, a total of 2,852 contacts were recorded. The household transmission rate was 16.1% (459/2,852) and rose according to the age (> 18 years) and lack of immunisation of the primary cases, and also the age (0-18 years), family relationship (siblings and children), lack of vaccination and chemoprophylaxis of contacts. Pertussis vaccine effectiveness in preventing new cases was 65.0% (95% confidence interval (CI): 11.6 to 86.2) for full vaccination (≥ 4 doses) and 59.7% (95% CI: -6.8 to 84.8) for incomplete vaccination (< 4 doses). The effectiveness of chemoprophylaxis was 62.1% (95% CI: 40.3 to 75.9). To reduce household transmission, contacts should be investigated to detect further cases and to administer chemoprophylaxis. The current vaccination status of cases and contacts can reduce household transmission.